Citeline

Don't miss our daily updates! Follow @Citeline on @LinkedIn : linkedin.com/company/citeli…

Citeline's APAC team is poised to link the dots that matter to you in real-time: vist.ly/4zjpd We proactively track trial trends and analyze policy shifts using data-led journalism, providing insights that will empower you in current industry discussions and decisions.

Everyone has an AI pilot. Very few have AI embedded in trial execution. This ebook focuses on where AI is delivering repeatable, real‑world impact across clinical trial workflows. Not just hype. Downlaod the ebook today: vist.ly/4zimw

🎙 Season 2 of #SmallBiotechsBigDecisions is now live! vist.ly/4zgzw A high-level conversation on how the biotech playbook is changing and what leaders need to think differently about as the industry enters its next phase. Watch the series and tune in now!

@FDA Read the announcement: fda.gov/news-events/pr…

On March 30, the US Food and Drug Administration (@FDA) reminded more than 2,200 medical product companies and researchers of the requirements to submit certain clinical trial results information to ClinicalTrials.gov. What you need to know: vist.ly/4zfe3

The future of life sciences leadership is here: vist.ly/4ze2k This release highlights 30 individuals who are not just advancing healthcare—but redefining it. This list isn’t just about recognition—it’s a signal of where the industry is heading next.

"Investors are still willing to bet on the small innovators fueling Big Pharma’s R&D coffers," says @IanLloyd, author of Citeline's annual Pharma R&D Review, in a @PharmaVoice article on the drug pipeline. Read now: vist.ly/4zd5r Get the report: vist.ly/4zd5t

A @Bloomberg column on how generic Ozempic is a game changer for China and India cited data from Citeline: vist.ly/4z9ih The world’s 2 most-populous countries are home to pharmaceutical companies capable of exploiting this to reshape the market for metabolic therapies.

What’s next in R&D, innovation, and clinical development? We will host a panel exploring the evolving industry landscape and what it means for your development strategy. Come join us at booth 34. Learn more and schedule a meeting: vist.ly/4z8h6

🚨 Regulatory disclosure rules keep shifting in subtle ways that can derail trial visibility and publication readiness. If you manage clinical trial disclosure, these changes matter. 🔗 March Roundup: vist.ly/4z5rh 🔗 Disclosure Monthly Roundups: vist.ly/4z5rk

🗓️ April 21 | 10am NYC | 3pm LDN What you’ll learn: -The key signals behind the latest pipeline data -Where innovation is accelerating — and where it’s slowing -Regional changes reshaping the landscape -Live discussion + audience Q&A Register now: vist.ly/4z3yx

Ready to see how AI is revolutionizing medtech? vist.ly/4yx25 
Download the new Medtech Insight eBook for expert analysis on dealmaking trends, patient-focused innovations, and real-world perspectives from clinicians and patients.

According to an article in @biospace highlighting key findings from Citeline’s Pharma R&D Annual Review, despite 2025 posting the first decline in overall global drug development since the mid-1990s, there are signs this may not be an extended fall-off. vist.ly/4yxz4

Join us for Pharma R&D Review Live 2026 on April 21 | 10am NYC | 3pm LDN for a data-driven look at what’s taking root across the pipeline — and what’s set to bloom next. Register here: vist.ly/4yvap

Let’s just say it’s all about unlocking smarter R&D decisions. Giving you a first glimpse of what’s coming to #SwissBiotechDay 2026. 🌿 Stop by booth 34 to find out more. vist.ly/4yu4z See you in Basel! @SwissBiotech

In an interview with @PharmExec, Matt Holms, Citeline’s VP of Commercial, Patient Engagement, and Recruitment, discusses ways clinical trial design and feasibility must adapt to address this evolving, multifaceted landscape. vist.ly/4yqpn

The future of pharma doesn’t wait—and neither should you: vist.ly/4ynxm Scrip Asks captures predictions from 300+ senior industry voices on the forces set to shape 2026, from dealmaking and data to AI and operational change.

Stay ahead of FDA shifts that could impact your strategy. vist.ly/4yi8m The landscape of drug approvals is evolving under new leadership and changing regulations. Save time and focus on what matters—accelerating life-saving therapies. Download our latest eBook now!

The long-range pipeline count shows a rare moment: 22,940 drugs in active R&D at the start of 2026 — down 3.92% vs. last year. Harvest the full story behind the shift — download the report. vist.ly/4yfdk